Breaks Categories: News

ThursdayMar 21, 2024 12:34 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well as clinical and regulatory progress made for the AIMIGo 3D VECG system. In addition, the company noted it had received two new patents during the period, covering HeartBeam’s proprietary technologies. “We have continued to make…

Continue Reading

WednesdayMar 20, 2024 12:57 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and…

Continue Reading

WednesdayMar 20, 2024 12:29 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. ET on March 26, 2024. Following that, the company’s Class A common stock will begin trading on the NASDAQ Capital Market on a split-adjusted basis. “The reverse split is intended to increase the per share trading price of the company’s common stock to enable the…

Continue Reading

TuesdayMar 19, 2024 12:36 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Welcomes Seasoned Tech, Product-Development Veteran as New CTO

HealthLynked (OTCQB: HLYK), a leader in healthcare technology innovation, announced that Chris Hall will the company’s new chief technology officer (CTO). Hall has gained invaluable expertise in technology and product development throughout his career; specifically, he has been involved in the launch of more than 100 products, has been responsible for more than a dozen patents and has managed global diverse teams. He comes to HealthLynked from Battelle, where he served as a senior product portfolio manager, and from HF Scientific, where he served as manager of new product development. Prior to that, he spent almost 20 years with Siemens…

Continue Reading

TuesdayMar 19, 2024 12:29 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per…

Continue Reading

TuesdayMar 19, 2024 12:07 pm

BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the…

Continue Reading

FridayMar 15, 2024 11:34 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human blood plasma that form the protein corona of the gold nanocrystals of CNM-Au8(R), Clene’s investigational drug in development for the treatment of neurodegenerative diseases. “The protein corona of CNM-Au8 gold nanocrystals, tailored for brain delivery…

Continue Reading

FridayMar 15, 2024 10:27 am

BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing product candidates designed to treat neurodegenerative disorders, has closed on its previously announced underwritten public offering. The offering was comprised of 6,571,428 shares of its common stock. According to the announcement, each share of common stock was sold at $1.75 per share, resulting in approximately $11.5 million in gross proceeds before deductions, commissions and expenses. Cognition Therapeutics anticipates using the funds from the offering for research, clinical development, process development and manufacturing, working capital, capital expenditures and other general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as…

Continue Reading

ThursdayMar 14, 2024 3:15 pm

BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study

BioNxt (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) has announced completion of the comparative pharmacokinetic (“PK”) study for its oral dissolvable film (“ODF”) based proprietary Cladribine product for the treatment of multiple sclerosis (“MS”). The company reported that the animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between BioNxt’s ODF product and the name-brand reference drug in all samples. “These results are a significant milestone for BioNxt. We have demonstrated that our ODF platform is an effective drug delivery system for cytostatic drugs via transmucosal absorption,” said BioNxt CEO Hugh Rogers. “With our recently…

Continue Reading

ThursdayMar 14, 2024 2:38 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission. The study is designed to evaluate the performance of a 12-lead ECG synthesized from the credit-card-sized HeartBeam AIMIGo(TM) system compared to a standard hospital-based 12-lead ECG; the study will use both quantitative and qualitative methodologies…

Continue Reading